Despite the positive in vitro and in vivo results observed with pharmacological blockade of Vegf in MM models, inhibition of Vegf in the clinical setting has not been successful, likely due to the contribution of other pro-angiogenic factors to this phenomena[75]. Here, VEGFA is linked to Miyoshi myopathy.